Deutsche Märkte geschlossen

Nabriva Therapeutics plc (NTY.SG)

Stuttgart - Stuttgart Verzögerter Preis. Währung in EUR
Zur Watchlist hinzufügen
1,6200+0,1400 (+9,46%)
Börsenschluss: 08:10AM CET

Nabriva Therapeutics plc

25-28 North Wall Quay
IFSC
Dublin 1
Ireland
353 1 649 2000
https://www.nabriva.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter73

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Theodore R. SchroederCEO & Director929,45kN/A1955
Dr. Steven P. Gelone Pharm. DPres, COO & Director931,67kN/A1968
Dr. Colin Broom M.D.Director39,78kN/A1956
Mr. Daniel DolanChief Financial Officer445,69kN/A1977
Mr. J. Christopher Naftzger BA, Esq., J.D.Gen. Counsel & Sec.N/AN/A1967
Ms. Jodi VanDerveerSr. VP & Head of HRN/AN/AN/A
Mr. Gary L. SenderConsultantN/AN/A1962
Dr. Christine J. Guico-Pabia M.B.A., M.D., M.P.H.Chief Medical OfficerN/AN/A1963
Mr. Werner HeilmayerVP of CMC & IPN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Corporate Governance

Nabriva Therapeutics plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.